Tags

Type your tag names separated by a space and hit enter

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Clin Infect Dis. 2008 May 15; 46(10):1499-509.CI

Abstract

BACKGROUND

The aim of this study was to show that sequential intravenous and oral moxifloxacin monotherapy (400 mg once per day) is as efficacious and safe as a combination regimen (intravenous ceftriaxone, 2 g once per day, plus sequential intravenous and oral levofloxacin, 500 mg twice per day) in patients hospitalized with community-acquired pneumonia.

METHODS

We conducted a prospective, multicenter, randomized, double-blind noninferiority trial. Patients with a Pneumonia Severity Index (PSI) of III-V were stratified on the basis of PSI risk class before randomization. The primary efficacy end point was clinical response at test of cure (4-14 days after the completion of treatment). Secondary efficacy end points were clinical and bacteriological response at end of treatment (days 7-14) and at follow-up assessment (21-28 days after the end of treatment), overall mortality, and mortality attributable to pneumonia.

RESULTS

Seven hundred thirty-three patients were enrolled in the study (368 in the moxifloxacin arm and 365 in the comparator arm); 49% had a PSI of IV, and 10% had a PSI of V. Of 569 patients (291 in the moxifloxacin arm and 278 in the comparator arm) valid for per-protocol analysis, the overall clinical cure rates at test of cure were 86.9% for moxifloxacin and 89.9% for the comparator regimen (95% confidence interval, -8.1% to 2.2%). Bacteriological success at test of cure was 83.3% for moxifloxacin and 85.1% for the comparator regimen (95% confidence interval, -15.4% to 11.8%). There were no significant differences between moxifloxacin and comparator treatments in the incidence of treatment-emergent adverse events or in mortality.

CONCLUSIONS

Monotherapy with sequential intravenous/oral moxifloxacin was noninferior to treatment with ceftriaxone plus levofloxacin combination therapy in patients with community-acquired pneumonia who required hospitalization.

Authors+Show Affiliations

Servei de Pneumologia i Allèrgia Respiratòria, Institut Clinic del Torax, Hospital Clínic de Barcelona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18419482

Citation

Torres, Antoni, et al. "Moxifloxacin Monotherapy Is Effective in Hospitalized Patients With Community-acquired Pneumonia: the MOTIV Study--a Randomized Clinical Trial." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 46, no. 10, 2008, pp. 1499-509.
Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clin Infect Dis. 2008;46(10):1499-509.
Torres, A., Garau, J., Arvis, P., Carlet, J., Choudhri, S., Kureishi, A., Le Berre, M. A., Lode, H., Winter, J., & Read, R. C. (2008). Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 46(10), 1499-509. https://doi.org/10.1086/587519
Torres A, et al. Moxifloxacin Monotherapy Is Effective in Hospitalized Patients With Community-acquired Pneumonia: the MOTIV Study--a Randomized Clinical Trial. Clin Infect Dis. 2008 May 15;46(10):1499-509. PubMed PMID: 18419482.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. AU - Torres,Antoni, AU - Garau,Javier, AU - Arvis,Pierre, AU - Carlet,Jean, AU - Choudhri,Shurjeel, AU - Kureishi,Amar, AU - Le Berre,Marie-Aude, AU - Lode,Hartmut, AU - Winter,John, AU - Read,Robert C, AU - ,, PY - 2008/4/19/pubmed PY - 2008/5/14/medline PY - 2008/4/19/entrez SP - 1499 EP - 509 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin. Infect. Dis. VL - 46 IS - 10 N2 - BACKGROUND: The aim of this study was to show that sequential intravenous and oral moxifloxacin monotherapy (400 mg once per day) is as efficacious and safe as a combination regimen (intravenous ceftriaxone, 2 g once per day, plus sequential intravenous and oral levofloxacin, 500 mg twice per day) in patients hospitalized with community-acquired pneumonia. METHODS: We conducted a prospective, multicenter, randomized, double-blind noninferiority trial. Patients with a Pneumonia Severity Index (PSI) of III-V were stratified on the basis of PSI risk class before randomization. The primary efficacy end point was clinical response at test of cure (4-14 days after the completion of treatment). Secondary efficacy end points were clinical and bacteriological response at end of treatment (days 7-14) and at follow-up assessment (21-28 days after the end of treatment), overall mortality, and mortality attributable to pneumonia. RESULTS: Seven hundred thirty-three patients were enrolled in the study (368 in the moxifloxacin arm and 365 in the comparator arm); 49% had a PSI of IV, and 10% had a PSI of V. Of 569 patients (291 in the moxifloxacin arm and 278 in the comparator arm) valid for per-protocol analysis, the overall clinical cure rates at test of cure were 86.9% for moxifloxacin and 89.9% for the comparator regimen (95% confidence interval, -8.1% to 2.2%). Bacteriological success at test of cure was 83.3% for moxifloxacin and 85.1% for the comparator regimen (95% confidence interval, -15.4% to 11.8%). There were no significant differences between moxifloxacin and comparator treatments in the incidence of treatment-emergent adverse events or in mortality. CONCLUSIONS: Monotherapy with sequential intravenous/oral moxifloxacin was noninferior to treatment with ceftriaxone plus levofloxacin combination therapy in patients with community-acquired pneumonia who required hospitalization. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/18419482/Moxifloxacin_monotherapy_is_effective_in_hospitalized_patients_with_community_acquired_pneumonia:_the_MOTIV_study__a_randomized_clinical_trial_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/587519 DB - PRIME DP - Unbound Medicine ER -